Latest Insider Transactions at Acelrx Pharmaceuticals Inc (ACRX)
This section provides a real-time view of insider transactions for Acelrx Pharmaceuticals Inc (ACRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ACELRX PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ACELRX PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2023
|
Badri N Dasu Chief Engineering Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,875
+19.64%
|
-
|
|
Feb 10
2023
|
Pamela P Palmer Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,125
+12.0%
|
-
|
|
Feb 10
2023
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
19,500
+22.07%
|
-
|
|
Feb 06
2023
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
458
-2.95%
|
$916
$2.02 P/Share
|
|
Feb 06
2023
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
681
-1.73%
|
$1,362
$2.02 P/Share
|
|
Feb 06
2023
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
617
-3.39%
|
$1,234
$2.02 P/Share
|
|
Feb 06
2023
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,982
-3.86%
|
$3,964
$2.02 P/Share
|
|
Jul 15
2022
|
Jill Marie Broadfoot |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+33.7%
|
-
|
|
Jul 15
2022
|
Marina Bozilenko |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+27.68%
|
-
|
|
Jul 15
2022
|
Richard Afable Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+29.11%
|
-
|
|
Jul 15
2022
|
Adrian Adams |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+6.82%
|
-
|
|
Jul 15
2022
|
Stephen J Hoffman |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+29.67%
|
-
|
|
Jul 15
2022
|
Howard B Rosen Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+14.12%
|
-
|
|
Jul 15
2022
|
Mark A Wan |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+29.67%
|
-
|
|
Jun 07
2022
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
46,400
+4.36%
|
$0
$0.22 P/Share
|
|
Mar 03
2022
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
23,051
-2.32%
|
$0
$0.41 P/Share
|
|
Mar 03
2022
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,923
-2.13%
|
$0
$0.41 P/Share
|
|
Mar 03
2022
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,612
-1.83%
|
$0
$0.41 P/Share
|
|
Mar 03
2022
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,923
-1.01%
|
$0
$0.41 P/Share
|
|
Feb 11
2022
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
23,058
-2.29%
|
$0
$0.4 P/Share
|
|
Feb 11
2022
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
390,000
+27.92%
|
-
|
|
Feb 11
2022
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,927
-2.11%
|
$0
$0.4 P/Share
|
|
Feb 11
2022
|
Raffi Asadorian Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
117,500
+23.81%
|
-
|
|
Feb 11
2022
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,615
-1.86%
|
$0
$0.4 P/Share
|
|
Feb 11
2022
|
Badri N Dasu Chief Engineering Officer |
BUY
Grant, award, or other acquisition
|
Direct |
97,500
+24.42%
|
-
|
|
Feb 11
2022
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,927
-1.01%
|
$0
$0.4 P/Share
|
|
Feb 11
2022
|
Pamela P Palmer Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
122,500
+13.5%
|
-
|
|
Feb 06
2022
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
27,318
-4.24%
|
$0
$0.43 P/Share
|
|
Feb 06
2022
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,391
-3.51%
|
$0
$0.43 P/Share
|
|
Feb 06
2022
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,830
-3.23%
|
$0
$0.43 P/Share
|
|
Feb 06
2022
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,391
-1.4%
|
$0
$0.43 P/Share
|
|
Nov 20
2021
|
Jill Marie Broadfoot |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Jun 17
2021
|
Mark G Edwards Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+3.69%
|
-
|
|
Jun 17
2021
|
Stephen J Hoffman |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+32.0%
|
-
|
|
Jun 17
2021
|
Marina Bozilenko |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+28.57%
|
-
|
|
Jun 17
2021
|
Richard Afable Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+31.01%
|
-
|
|
Jun 17
2021
|
Howard B Rosen Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+11.27%
|
-
|
|
Jun 17
2021
|
Adrian Adams |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+4.85%
|
-
|
|
Jun 17
2021
|
Mark A Wan |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+32.0%
|
-
|
|
Mar 30
2021
|
Marina Bozilenko |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Mar 03
2021
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+23.9%
|
-
|
|
Mar 03
2021
|
Raffi Asadorian Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,750
+20.87%
|
-
|
|
Mar 03
2021
|
Badri N Dasu Chief Engineering Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+19.63%
|
-
|
|
Mar 03
2021
|
Pamela P Palmer Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,750
+9.35%
|
-
|
|
Feb 11
2021
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
23,052
-5.11%
|
$46,104
$2.63 P/Share
|
|
Feb 11
2021
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,915
-1.48%
|
$17,830
$2.63 P/Share
|
|
Feb 11
2021
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,775
-4.47%
|
$13,550
$2.63 P/Share
|
|
Feb 11
2021
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,024
-4.69%
|
$18,048
$2.63 P/Share
|
|
Feb 06
2021
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
25,059
-5.26%
|
$50,118
$2.59 P/Share
|
|
Feb 06
2021
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,414
-1.54%
|
$18,828
$2.59 P/Share
|